Skip to main content
Premium Trial:

Request an Annual Quote

InformedDNA, NIA Magellan Collaborate on Genetics Benefits

NEW YORK (GenomeWeb) – InformedDNA announced on Monday a collaboration with NIA Magellan to offer an evidence-based genetics benefits program.

As the number of commercially available genetic tests and the inappropriate use of such tests grow rapidly, the collaboration "provides a critical solution by offering genetic testing guidance by independent genetics specialists to patients and physicians alike," St. Petersburg, Fla.-based InformedDNA said in a statement.

The company has a national network of board-certified genetics specialists to provide clinical review services, ensuring appropriate use of genetics tests and delivering cost savings, it said. It will couple its services with NIA Magellan's solutions to deliver cost-effective and clinically actionable genetic testing, it added.

NIA Magellan is a division of healthcare management firm Magellan Health.

"[D]eploying InformedDNA's genetics expertise within NIA Magellan's established technology infrastructure allows InformedDNA to continue our rapid growth with health plan customers of all sizes," InformedDNA CEO David Nixon said.  

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.